



# VIRUS RESEARCH

An International Journal of Molecular and Cellular Virology

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

---

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.5</b>



ISSN: 0168-1702

### DESCRIPTION

---

*Virus Research* provides a means of fast publication for original papers on fundamental research in **virology**. Contributions on new developments concerning **virus structure, replication, pathogenesis** and **evolution** are encouraged. These include reports describing virus **morphology**, the function and **antigenic analysis** of virus structural components, virus **genome** structure and expression, analysis on virus **replication processes**, virus evolution in connection with **antiviral interventions**, effects of viruses on their **host cells**, particularly on the **immune system**, and the pathogenesis of virus infections, including oncogene activation and transduction. The journal also publishes review articles on topics of current interest, special issues focused on a defined subject, and occasional book reviews and meeting reports.

#### Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our support pages: <http://support.elsevier.com>

### AUDIENCE

---

All virologists

### IMPACT FACTOR

---

2013: 2.827 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

---

BIOSIS  
Elsevier BIOBASE  
Chemical Abstracts  
Current Contents/Life Sciences  
MEDLINE®  
EMBASE  
Pascal et Francis (INST-CNRS)  
Reference Update  
Scopus

## EDITORIAL BOARD

---

### *Editor-in-Chief:*

#### ***RNA Viruses and Virus Vectors***

**Luis Enjuanes, Ph D.**, Department of Molecular and Cell Biology, National Center of Biotechnology, Spanish National Research Council (CNB-CSIC), Campus Universidad Autónoma de Madrid, Darwin 3. Cantoblanco, 28049, Madrid, Spain

### *Editors:*

#### ***Retroviruses, RNA mechanisms and RNAi***

**Ben Berkhout, Ph D.**, Laboratory of Experimental Virology, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands

#### ***RNA Viruses and Virus Evolution***

**Esteban Domingo, Ph D.**, Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain

#### ***RNA Viruses and Virus-host Interaction***

**Adolfo Garcia-Sastre, Ph D.**, Department of Microbiology, Department of Medicine, Division of Infectious Diseases, Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY 10029, USA

#### ***DNA Viruses***

**Dennis O'Callaghan, Ph D.**, Department of Microbiology and Immunology, Louisiana State University (LSU), Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA

#### ***Plant and Fungal Viruses***

**Nobuhiro Suzuki, Ph D.**, Institute of Plant Science and Resources (IPSR), Okayama University, Chou 1-20-1, Kurashiki 710-0046 Okayama, Japan

#### ***RNA Viruses, Immune Responses, and Virus-host interaction***

**Volker Thiel, Ph D.**, Institute of Immunology, Kanton Hospital St. Gallen, St. Gallen, and VetSuisse Faculty, University of Zürich, Switzerland

### *Founding Editor:*

**B.W.J. Mahy**

### *Editorial Board:*

**M. Ackermann**, Universität Zürich, Zürich, Switzerland

**F. Almazan**, Centro Nacional de Biotecnología-CSIC, Madrid, Spain

**W. Atwood**, Brown University, Providence, Rhode Island, USA

**L. Banks**, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy

**A.D.T. Barrett**, University of Texas Medical Branch, Galveston, USA

**M. Beer**, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany

**S-E Behrens**, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany

**M. Bendinelli**, Università di Pisa, Pisa, Italy

**M. Borca**, United States Department of Agriculture, Greenport, New York, USA

**W. Britt**, University of Alabama at Birmingham, Birmingham, Alabama, USA

**I-R. Choi**, International Rice Research Institute (IRRI), Metro Manila, Philippines

**P.R. Clapham**, University of Massachusetts Medical School, Worcester, Massachusetts, USA

**P.L. Collins**, Johns Hopkins University School of Medicine, Bethesda, Maryland, USA

**R.W. Compans**, Emory University, Atlanta, Georgia, USA

**R.C. Condit**, University of Florida, Gainesville, Florida, USA  
**K. Conzelmann**, Technische Universität München, München, Germany  
**R.J. de Groot**, Utrecht University, Utrecht, Netherlands  
**T. Dermody**, Vanderbilt University Medical Center, Nashville, Tennessee, USA  
**U. Desselberger**, University of Cambridge (Addenbrooke's Hospital), Cambridge, UK  
**W. Doerfler**, Universität zu Köln, Köln, Germany  
**J.D. Drexler**, University of Bonn Medical Centre, Bonn, Germany  
**Chr. Drosten**, University of Bonn Medical Centre, Bonn, Germany  
**J.H. Elder**, The Scripps Research Institute, La Jolla, California, USA  
**R. Elliot**, University of Glasgow, Glasgow, Scotland, UK  
**K. Faaberg**, United States Department of Agriculture, Ames, Iowa, USA  
**D. Fargette**, Centre IRD Montpellier, Montpellier, France  
**H. Feldmann**, National Institutes of Health (NIH), Hamilton, Montana, USA  
**A. Fernandez-Sesma**, Mount Sinai School of Medicine, New York, New York, USA  
**B. Fleckenstein**, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany  
**R. Flores**, Consejo Superior de Investigaciones Científicas (CSIC), Valencia, Spain  
**T.M. Folks**, Southwest Foundation for Biomedical Research, San Antonio, Texas, USA  
**R.A.M. Fouchier**, Erasmus MC: Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands  
**L. Frappier**, University of Toronto, Toronto, Ontario, Canada  
**U. Garaigorta**, The Scripps Research Institute, La Jolla, California, USA  
**J.A. Garcia**, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain  
**J.V. Garcia**, University of Texas, Dallas, Texas, USA  
**P. Gastaminza**, Centro Nacional de Biotecnología-CSIC, Madrid, Spain  
**A. Gatignol**, McGill University, Montréal, Quebec, Canada  
**A.E. Gorbalenya**, Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands  
**E. Gowans**, University of Adelaide, Woodville South, Australia  
**D.E. Griffin**, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA  
**L. Guarino**, Texas A&M University, College Station, Texas, USA  
**B.G. Hale**, MRC-University of Glasgow, Glasgow, Scotland, UK  
**R.N. Harty**, University of Pennsylvania, Philadelphia, Pennsylvania, USA  
**M. Heise**, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA  
**B.I. Hillman**, Rutgers University, New Brunswick, New Jersey, USA  
**J. Hu**, Pennsylvania State University, Hershey, Pennsylvania, USA  
**M. Ishikawa**, Institute of Agrobiological Sciences, Tsukuba, Japan  
**S. Jameel**, ICGEB - India, New Delhi, India  
**C. Jones**, University of Nebraska at Lincoln, Lincoln, Nebraska, USA  
**I. Jones**, University of Reading, Reading, UK  
**Y. Kawaguchi**, University of Tokyo, Minato-Ku, Japan  
**K.-H. Kim**  
**P. Kinchington**, University of Pittsburgh, Pittsburgh, Pennsylvania, USA  
**E.J. Kremer**, Centre National de la Recherche Scientifique (CNRS), Montpellier, France  
**S. Kunz**, Centre Hospitalier Universitaire Vaudois Lausanne (CHUV), Lausanne, Switzerland  
**K. Leppard**, University of Warwick, Coventry, UK  
**W.I. Lipkin**, University of Columbia, New York, New York, USA  
**S.A. Lommel**, North Carolina State University, Raleigh, North Carolina, USA  
**R.B. Luftig**, Louisiana State University, New Orleans, Louisiana, USA  
**J. Mak**, Deakin University, Waurin Ponds, Victoria, Australia  
**S. Makino**, University of Texas Medical Branch, Galveston, USA  
**A. Marcello**, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy  
**L. Martinez-Sobrido**, University of Rochester Medical Center, Rochester, New York, USA  
**W.S. Mason**, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA  
**C. Masuta**, Hokkaido University, Sapporo, Japan  
**M.G. Mateu**, Universidad Autónoma de Madrid, Madrid, Spain  
**J. McCauley**, The Pirbright Institute, Newbury, UK  
**L. Menendez-Arias**, Centro de Biología Molecular Severo Ochoa, Madrid, Spain  
**X.J. Meng**, Virginia Polytechnic Institute & State University, Blacksburg, Virginia, USA  
**C. Meyers**, Penn State University College of Medicine, Hershey, Pennsylvania, USA  
**K. Mise**, Kyoto University, Kyoto, Japan  
**P.S. Moore**, University of Pittsburgh, Pittsburgh, Pennsylvania, USA  
**I. Morgan**, MRC-University of Glasgow, Glasgow, Scotland, UK  
**M.P. Murtaugh**, University of Minnesota, St. Paul, Minnesota, USA  
**H. Nauwynck**, Universiteit Gent, Merelbeke, Belgium  
**A. Nomoto**, University of Tokyo, Bunkyo-Ku, Japan  
**F. Novembre**, Emory University, Atlanta, Georgia, USA  
**K. Ohshima**, Saga University, Honjo-machi, Japan  
**D.A. Ornelles**, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA  
**F.A. Osorio**, University of Nebraska at Lincoln, Lincoln, Nebraska, USA

**N. Osterrieder**, Freie Universität Berlin, Berlin, Germany  
**V. Pallas**, CSIC-Universidad Politecnica de Valencia, Valencia, Spain  
**P. Palukaitis**, Scottish Crop Research Institute, Invergowrie, Dundee, UK  
**P. Pellett**, Wayne State University School of Medicine, Detroit, Michigan, USA  
**S. Perلمان**, University of Iowa, Iowa City, Iowa, USA  
**T. Pietschmann**, Medizinische Hochschule Hannover (MH Hannover), Hannover, Germany  
**A. Plyusnin**  
**R. Ray**, St. Louis University Health Science Center, St. Louis, Missouri, USA  
**R. Rico-Hesse**, Southwest Foundation for Biomedical Research, San Antonio, Texas, USA  
**J. Ridpath**, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), Ames, Iowa, USA  
**B. Rima**, Queen's University Belfast, Belfast, UK  
**J.F. Rodríguez**, Centro Nacional de Biotecnología-CSIC, Madrid, Spain  
**L. Roux**, Université de Genève, Genève 4, Switzerland  
**P. Roy**, London School of Hygiene and Tropical Medicine, London, England, UK  
**L. Ruan**, Chinese Center for Disease Control, Beijing, China  
**S. Samal**  
**J.T. Sample**, Penn State University College of Medicine, Hershey, Pennsylvania, USA  
**M.J. Sapp**, Louisiana State University (LSU) Health Sciences Center, Shreveport, Louisiana, USA  
**C.S. Schmaljohn**, US AMRIID, Fort Detrick, Maryland, USA  
**M. Schnell**, Thomas Jefferson University, Philadelphia, Pennsylvania, USA  
**M. Schweizer**, Universität Bern, Bern, Switzerland  
**A. Siddiqui**, University of California at San Diego (UCSD), La Jolla, California, USA  
**A.J. Sinclair**, University of Sussex, Falmer, Brighton, England, UK  
**B. Slagle**, Baylor College of Medicine, Houston, Texas, USA  
**E. Snijder**, Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands  
**I. Sola**, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain  
**K.R. Spindler**, University of Michigan Medical School, Ann Arbor, Michigan, USA  
**D.C. Stenger**, U.S. Department of Agriculture (USDA), Agricultural Research Service (ARS), Parlier, California, USA  
**M.J. Studdert**, University of Melbourne, Parkville, Victoria, Australia  
**M. Suthar**, Emory University, Atlanta, USA  
**F. Thierry**, Agency for Science, Technology and Research (A\*STAR), Singapore, Singapore  
**M. Turina**, Istituto di Virologia Vegetale, Torino, Italy  
**A.C. van der Kuyl**, Universiteit van Amsterdam, Academisch Medisch Centrum (AMC), Amsterdam, Netherlands  
**F. van Kuppeveld**, Utrecht University, Utrecht, Netherlands  
**C. van Lint**, Université Libre de Bruxelles (ULB), Gosselies, Belgium  
**M. Vignuzzi**, Institut Pasteur, Paris cedex 15, France  
**V.G. Wilson**, Texas A&M University, College Station, Texas, USA  
**D. Yoo**, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA  
**S. Zuñiga**, Centro Nacional de Biotecnología-CSIC, Madrid, Spain  
**R. Züst**, Agency for Science, Technology and Research (A\*STAR), Singapore

## GUIDE FOR AUTHORS

---

### INTRODUCTION

*Virus Research* provides a means of fast publication for original papers on fundamental research in virology. Contributions on new developments concerning virus structure, replication, pathogenesis and evolution are encouraged. These include reports describing virus morphology, the function and antigenic analysis of virus structural components, virus genome structure and expression, analysis on virus replication processes, virus evolution in connection with antiviral interventions, effects of viruses on their host cells, particularly on the immune system, and the pathogenesis of virus infections, including oncogene activation and transduction. The journal also publishes review articles on topics of current interest, special issues focused on a defined subject, and occasional book reviews and meeting reports.

### Types of Papers

*Research articles* should generally be divided into Summary, Introduction, Materials and Methods, Results, Discussion and Acknowledgements and References.

*Short communications*, approximately 8 typewritten pages in total, including a summary, illustrations and keywords but written without section headings.

*Review articles* on topics of current interest in Virology will be published. While some authors will be invited to write reviews, others wishing to contribute a review article are invited to contact Dr. Luis Enjuanes at L.Enjuanes@cnb.csic.es.

*Book Reviews or Meeting Reports.*

### BEFORE YOU BEGIN

#### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

#### **Conflict of interest**

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

No article can be publicised as in the press, or under revision, until the author has received an acceptance letter from the Editor. No prior acceptance pdf should be put online under **any** circumstance.

#### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

#### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by

the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Copyright**

This journal offers authors a choice in publishing their research: Open access and Subscription.

#### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

#### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

### **Retained author rights**

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.

Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY):** lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee in this journal is **\$2200**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

## **PREPARATION**

### **Use of word processing software**

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.



Characters not available on your wordprocessor should not be left open but indicated by a unique code (e.g., alpha, @, #, etc. for the Greek letter  $\alpha$ ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to introduce word splits.

## Article structure

### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to "the text". Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Please ensure that all manuscript pages are numbered and that the lines on each page are also numbered. This will greatly assist the review process for your paper.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

## Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

## Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

## Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum



of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: [Illustration Service](#).

### **Highlights**

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### **Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### **Nomenclature and units**

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI.

### **Virus nomenclature**

Each virus should be identified at least once, preferably in the 'Introduction' or 'Materials and Methods' section, using formal family, genus, and species terms and where possible by using a precise strain designation term as developed by an internationally recognized specialty group or culture collection. Please note that the word type is not used before species designations that include a number. Formal terms used for virus families, genera, and species should be those approved by the International Committee on Taxonomy of Viruses (ICTV): Viral Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses (ICTV) by Andrew M. Q. King, Elliot J. Lefkowitz, Michael J. Adams and Eric. B. Carstens. October 2011 This volume also includes standard abbreviations for species. Once formal taxonomic names have been given in a paper, vernacular terms may be used.

### **Formal taxonomic nomenclature**

In formal taxonomic usage, the first letters of virus order, family, subfamily, genus and species names are capitalized and the terms are printed in italics. Other words in the species names are not capitalized unless they are proper nouns or parts of nouns, for example *West Nile virus*. In formal usage, the name of the taxon should precede the term for the taxonomic unit; for example; "the family *Paramyxoviridae*," "the genus *Morbillivirus*." The following represent examples of full formal taxonomic terminology:

1. Order *Mononegavirales*, family *Rhabdoviridae*, genus *Lyssavirus*, species *Rabies virus*.
2. Family *Poxviridae*, subfamily *Chordopoxvirinae*, genus *Orthopoxvirus*, species *Vaccinia virus*.
3. Family *Picornaviridae*, genus *Enterovirus*, species *Poliovirus*.
4. Family *Bunyaviridae*, genus *Tospovirus*, species *Tomato spotted wilt virus*.

### *Vernacular Taxonomic Nomenclature*

In formal vernacular usage, virus order, family, subfamily, genus and species names are written in lower case Roman script: they are not capitalized, nor are they printed in italics or underlined. In informal usage, the name of the taxon should not include the formal suffix, and the name of the taxon should follow the term for the taxonomic unit; for example "the picornavirus family, the enterovirus genus." One particular source of ambiguity in vernacular nomenclature lies in the common use of the same root terms in formal family, genus or species names. Imprecision stems from not being able to easily identify in vernacular usage which hierarchical level is being cited. For example, the vernacular name "*paramyxovirus*" might refer to the family *Paramyxoviridae*, or one species in the genus *Respirovirus*, such as *Human parainfluenza virus 1*. The solution in vernacular usage is to avoid "jumping" hierarchical levels and to add taxon identification wherever needed. For example, when citing the taxonomic placement of *Human parainfluenza virus 1*, taxon identification should always be added: *Human Parainfluenza virus 1* is a species in the genus *Respirovirus*, family *Paramyxoviridae*. In this example, as is usually the case, adding the information that this virus is also a member of the subfamily *Paramyxovirinae* and the order *Mononegavirales* is unnecessary.

It should be stressed that italics and capital initial letters need be used only if the species name refers to the taxonomic category. When the name refers to viral objects such as virions present in a preparation or seen in an electron micrograph, italics and capital initial letters are not needed and the names are written in lower case Roman script. This also applies when the names are used in adjectival form, for instance tobacco mosaic virus polymerase. The use of italics when referring to the name of a species as a taxonomic entity signals that it has the status of an officially recognized species. Please consult: *Viral Taxonomy. Ninth Report of the International Committee on Taxonomy of Viruses (ICTV)* by Andrew M. Q. King, Elliot J. Lefkowitz, Michael J. Adams and Eric. B. Carstens (October 2011) to ascertain which names have been approved as official species names. When the taxonomic status of a new putative species is uncertain or its position within an established genus has not been clarified, it is considered a tentative species and its name is not written in italics although its initial letter is capitalized.

*Origins of bioreagents* - The origins of bioreagents should be described adequately, including citation of culture collections, companies, or colleagues from whom the bioreagents were obtained. If viruses were collected from nature, the collecting site and procedure should also be properly described. Bioreagents include but are not necessarily limited to virus strains and species, antibodies, and cell lines.

### **Database linking**

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

### **Artwork**

#### *Electronic artwork*

#### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

#### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

#### **References**

##### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

##### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### *Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

### *Reference style*

*Text:* All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
2. *Two authors:* both authors' names and the year of publication;
3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ....'

*List:* References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

### *Examples:*

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59.

Reference to a book:

Strunk Jr, W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

### *Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>.

Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

### **AFTER ACCEPTANCE**

#### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.



### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

### **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>